FRANCIS MEDRANDA: Open Payments
NPI 1982486023 · CORAL SPRINGS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,999 in 81 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $259 · 2025 $1,999
Food & beverage: $1,999
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 19 | $484 |
| GENZYME CORPORATION | 15 | $393 |
| GlaxoSmithKline, LLC. | 16 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $153 |
| Genentech, Inc. | 1 | $139 |
| CSL Behring | 5 | $114 |
| AstraZeneca Pharmaceuticals LP | 5 | $108 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $52 |
| BioCryst US Sales Co., LLC | 2 | $52 |
| Cycle Pharmaceuticals Inc | 2 | $49 |
Products named: DUPIXENT, Xolair, HYQVIA, NUCALA, TRELEGY ELLIPTA, Haegarda, TEZSPIRE, NEFFY.
Industry payments across FL — which companies pay providers there.
